Sanara MedTech Inc.

Sanara MedTech Inc.

SMTINYSE / NASDAQHealthcareSmall cap

$32.55-$0.12 (-0.4%)

Last close · Data as of Nov 20, 2026

Market cap
$202.7M
P/E
-5.4x
EV / EBITDA
22.7x
Revenue
$103.1M
Net margin
-36.4%
ROCE
16.8%

+70.1% over the last year

Sanara MedTech Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.8%
3M
-4.9%
6M
+41.5%
1Y
+70.1%
5Y
+3.9%

52-week range

Day change -$0.12 (-0.4%) from $33 to $33 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SMTI, bought on each weekday since 2021.

News & filings

What Sanara MedTech filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 37.6 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 68.7% in fiscal 2025, 49.7 points more than revenue.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.

Read moreShow less

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Sector
Healthcare
Shares outstanding
8.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$202.7M
P/E
-5.4x
P/B
34.1x
EV / EBITDA
22.7x
EV / Sales
2.3x
P/S
2.0x
52-week high
$35.28
52-week low
$16.34

Profitability

Operating margin
8.9%
Net margin
-36.4%
EBITDA margin
10.0%
ROE
-632.5%
ROCE
16.8%
ROIC
13.4%
ROA
-51.5%
Asset turnover
1.41

Growth

Revenue
$103.1M
Revenue growth, 1Y
19.0%
Revenue CAGR, 3Y
31.0%
Net profit growth, 1Y
288.7%
Free cash flow
$2.1M

Solvency

Current ratio
1.80
Debt / Equity
8.12
Debt / Assets
0.66
CFO / Net profit
-0.18
Cash / Market cap
8.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$103.1M
Cost of revenue$7.5M
Gross profit$95.6M
Operating expenses$86.5M
Research and development$5.1M
Selling, general and administrative$78.7M
Operating income$9.2M
Interest and other-$9.5M
Pretax income-$390.0k
Tax and other$37.2M
Net income-$37.6M

Revenue and net profit

Revenue grew 19.0% in FY2025; net profit is the dashed line.

Sanara MedTech Inc. revenue and net profit by fiscal year
Sanara MedTech Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$45.8M-$7.9M
FY2023$65.0M-$4.3M
FY2024$86.7M-$9.7M
FY2025$103.1M-$37.6M

Cash flows

FY2025: $6.8M from operations, $2.1M free after investment (dashed).

Sanara MedTech Inc. operating and free cash flow by fiscal year
Sanara MedTech Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$5.6M-$6.3M
FY2023-$3.2M-$3.5M
FY2024-$23.8k-$253.1k
FY2025$6.8M$2.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$103.1M+19.0%1Y
EBITDA
$10.3M+68.7%1Y
Net profit
-$37.6M
Cash from operations
$6.8M
Free cash flow
$2.1M
Revenue CAGR, 3Y
31.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$103.1M$10.3M-$37.6M$2.1M-632.5%+19.0%+288.7%

Monthly returns

Month-by-month returns of SMTI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$72.9M
Liabilities$67.0M
Equity$5.9M
Paid-in capital$81.2M
Retained earnings-$75.3M
Minority interest-$10.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SMTI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Sanara MedTech Inc. (this company)2.3x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Sanara MedTech Inc.SMTIthis company$202.7M-5.4x34.1x-632.5%22.7x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Peer median—-2.7x0.8x-24.0%0.7x

Year-to-date ROI

SMTI since 1 January, against earlier years.

Historical volatility

SMTI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Sanara MedTech Inc. operating margin by fiscal year
Sanara MedTech Inc. operating margin by fiscal year
DateOperating margin
FY2022-26.7%
FY2023-11.8%
FY20241.4%
FY20258.9%
LineFY2025
Cost of revenueCost Of Revenue$7.5M
Gross profitGross Profit$95.6M
Operating expensesOperating Expense$86.5M
Research and developmentResearch And Development$5.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$2.7M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$2.7M
Total expensesTotal Expenses$94.0M
Pretax incomePretax Income-$390.0k

Learn while you research

Academy chapters picked for Sanara MedTech Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 8.12 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →